

**Table 1 Overview of included studies and their study names, Adults with Restless Legs Syndrome**

<b>Study Name</b>	<b>Reference (Main reference highlighted in colour)</b>
<b>Allen 2011</b>	Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. <i>Sleep Med.</i> 2011;12(9):906-913.
<b>Cho 2016</b>	Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. <i>Sleep Med.</i> 2016;25:16-23. Cho Y, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patient with restless legs syndrome. <i>Sleep. Conference: 30th annual meeting of the associated professional sleep societies, LLC, SLEEP 2016. Denver, CO united states. Conference start: 20160611. Conference end: 20160615. Conference publication: (var.pagings).</i> 2016;39:A227-a228
<b>Davis 2000</b>	Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. <i>Eur Neurol.</i> 2000;43(2):70-75.
<b>Earley 2009</b>	Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. <i>Sleep Med.</i> 2009;10(2):206-211.
<b>Grote 2009</b>	Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. <i>Mov Disord.</i> 2009;24(10):1445-1452.
<b>Lee 2014</b>	Lee CS, Lee SD, Kang SH, Park HY, Yoon IY. Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin. <i>Eur J Neurol.</i> 2014;21(2):260-266. Yoon I, Lee C, Lee S, Kang S, Park H. Comparison of efficacy between oral iron and dopamine agonists in the treatment of patients with restless legs syndrome with low-normal serum ferritin. <i>Sleep.</i> 2013;36:A247.
<b>Trenkwalder 2017</b>	Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. <i>Mov Disord.</i> 2017. Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A. Single-dose ferric carboxymaltose for the treatment of restless legs syndrome in iron deficient non-anaemic patients-a randomized, placebo-controlled trial. <i>Journal of Sleep Research. Conference: 23rd Congress of the European Sleep Research Society, ESRS 2016. Italy. Conference Start: 20160913. Conference End: 20160916.</i> 2016;25:67-68.
<b>Wang 2009</b>	Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. <i>Sleep Med.</i> 2009;10(9):973-975.

Table 2 Overview of the outcomes analysed, Adults with Restless Legs Syndrome

Outcome	RLS Symptom Severity	RLS Treatment Response	Sleep	Sleepiness	Quality of Life	Global Impression Rating	Change in Global Impression, Inventory or Rating	Depression	Fatigue	Adverse Events	Serious Adverse Events
Study Name											
Allen 2011	4	4	4		4		4		4	4	EOS
Cho 2016	6	6	6		6						6
Davis 2000			[12]		12					[14]	
Earley 2009	2	2				2				[2*]	
Grote 2009	11	11								52	
Lee 2014	12	12	12	12				12			
Trenkwalder 2017	12	12		[12]		12	12			12	12
Wang 2009	12				[12]						12

The numbers in the fields denote the analysed follow-up period in weeks. Reported, but not poolable, outcomes are presented in brackets "[ ]".

\*Earley 2009 reports side effects at day of infusion and adverse effects at 2 weeks.

Abbreviations: EOS, End of Study

**Table 3: Overview of included studies and their study names, Fatigued women**

Study Name	Reference (Main reference highlighted in colour)
<b>FERRIM (Krayenbuehl 2011)</b>	Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. <i>Blood</i> . 2011;118(12):3222-3227.
<b>PREFER (Favrat 2014)</b>	Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. <i>PLoS one</i> . 2014;9(4):e94217.
	Favrat B, Balck K, Gasche C, et al. A single 1000mg iron dose of ferric carboxymaltose improves fatigue in iron deficient, non-anaemic premenopausal women - Results of the randomised, placebo-controlled prefer study. <i>International journal of gynaecology and obstetrics</i> . 2012;119:S858-s859.
	Favrat B, Balck K, Gasche C, et al. One 1000 mg iron dose of ferric carboxymaltose improved fatigue in iron-deficient, non-anaemic women in the randomised placebo-controlled study PREFER. <i>BJOG</i> . 2012;119:232-233.
<b>Vaucher 2012</b>	Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. <i>Cmaj</i> . 2012;184(11):1247-1254.
<b>Verdon 2003</b>	Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. <i>Bmj</i> . 2003;326(7399):1124.

**Table 4 Overview of the outcomes analysed, Fatigued women**

Outcome	Fatigue Severity	Fatigue Improvement	Quality of Life	Depression	Anxiety	Adverse Events	Serious Adverse Events
<b>Study Name</b>							
FERRIM (Krayenbuehl 2011)	12	12				12	12
PREFER (Favrat 2014)	8	8	8			8	8
Vaucher 2012	12		12	12	12		
Verdon 2003	4			4	4		

The numbers in the fields denote the analysed follow-up period in weeks.

**Table 5 Overview of included studies and their study names, Children with ADHD**

Study Name	Reference (Main reference highlighted in colour)
<b>Konofal 2008</b> {Konofal, 2008 #48}	Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. <i>Pediatr Neurol.</i> 2008;38(1):20-26.

**Table 6 Overview of the outcomes analysed, Children with ADHD**

Outcome	ADHD	Clinical Global Impression	Restless Legs Syndrome Diagnosis	Adverse Events
Study Name				
Konofal 2008	12	12	12	12

The numbers in the fields denote the analysed follow-up period in weeks.